Table 1. Immunocytochemical staining for Insulin, Glucagon, SRIF and IAPP.
|
Diabetic subjects no. |
Age/sex/ history |
Large islets |
Medium-sized islets |
Extra-large islets |
|||||||||||||||
| Total % |
β % |
σ % |
δ % |
IAPP/β |
(n) |
Total % |
β % |
σ % |
δ % |
IAPP/β |
(n) |
Total % |
β % |
σ % |
δ % |
IAPP/β |
(n) |
||
| Case 1 |
38/M/1 |
64 |
54 |
35 |
9 |
24 |
(8) |
39 |
49 |
40 |
13 |
27 |
(17) |
|
|
|
|
|
|
| Case 2 |
62/F/2 |
73 |
43 |
46 |
11 |
21 |
(11) |
42 |
48 |
42 |
13 |
20 |
(9) |
151 |
46 |
46 |
8 |
24 |
(5) |
| Case 3 |
50/F/1 |
77 |
45 |
49 |
8 |
29 |
(6) |
37 |
54 |
34 |
12 |
30 |
(5) |
183 |
38 |
53 |
7 |
21 |
(14) |
| Case 4 |
62/F/3 |
68 |
51 |
43 |
10 |
40 |
(6) |
40 |
40 |
50 |
10 |
25 |
(6) |
146 |
38 |
50 |
10 |
24 |
(13) |
| Case 5 |
50/F/1 |
74 |
40 |
51 |
9 |
23 |
(14) |
37 |
40 |
48 |
12 |
33 |
(5) |
122 |
36 |
52 |
8 |
22 |
(6) |
| Case 6 |
77/M/3 |
67 |
36 |
53 |
14 |
27 |
(6) |
33 |
37 |
48 |
20 |
39 |
(19) |
|
|
|
|
|
|
| Case 7 |
71/F/4 |
83 |
45 |
43 |
11 |
24 |
(7) |
37 |
36 |
50 |
14 |
22 |
(6) |
158 |
38 |
50 |
17 |
20 |
(12) |
| Case 8 |
52/F/1 |
68 |
38 |
54 |
8 |
25 |
(10) |
41 |
34 |
55 |
10 |
29 |
(11) |
130 |
43 |
53 |
6 |
35 |
(4) |
| Case 9 |
53/M/1 |
82 |
38 |
57 |
5 |
20 |
(10) |
13 |
41 |
44 |
12 |
35 |
(5) |
140 |
39 |
55 |
4 |
23 |
(10) |
| Case 10 |
49/M/1 |
77 |
31 |
53 |
16 |
27 |
(7) |
37 |
30 |
51 |
14 |
19 |
(8) |
144 |
39 |
47 |
14 |
16 |
(10) |
| Case 11 |
54/M/2 |
73 |
27 |
55 |
18 |
24 |
(12) |
38 |
35 |
46 |
19 |
24 |
(5) |
127 |
31 |
51 |
18 |
27 |
(8) |
| Case 12 |
62/F/3 |
77 |
40 |
52 |
9 |
18 |
(9) |
39 |
33 |
53 |
13 |
23 |
(9) |
116 |
33 |
56 |
7 |
21 |
(7) |
| Case 13 |
63/M/3 |
71 |
26 |
65 |
9 |
26 |
(10) |
34 |
39 |
49 |
9 |
27 |
(9) |
150 |
21 |
72 |
7 |
24 |
(6) |
| Case 14 |
64/M/2 |
76 |
31 |
53 |
16 |
29 |
(11) |
39 |
38 |
48 |
13 |
21 |
(6) |
144 |
30 |
54 |
15 |
30 |
(8) |
| Case 15 |
75/M/4 |
77 |
38 |
52 |
11 |
17 |
(8) |
37 |
32 |
54 |
13 |
21 |
(6) |
140 |
32 |
58 |
10 |
16 |
(11) |
| Case 16 |
65/M/2 |
72 |
32 |
56 |
16 |
30 |
(11) |
38 |
35 |
51 |
16 |
25 |
(9) |
129 |
33 |
53 |
12 |
20 |
(5) |
| Case 17 |
66/M/3 |
67 |
28 |
53 |
16 |
24 |
(9) |
40 |
31 |
50 |
18 |
24 |
(11) |
143 |
30 |
57 |
11 |
22 |
(5) |
| Case 18 |
67/F/3 |
71 |
33 |
59 |
75 |
30 |
(12) |
34 |
40 |
53 |
13 |
33 |
(8) |
122 |
32 |
64 |
7 |
27 |
(5) |
| Mean |
|
77 |
37 |
51 |
11 |
25 |
(167) |
38 |
38 |
48 |
13 |
26 |
(154) |
140 |
35 |
54 |
10 |
23 |
|
| SE |
|
1.2 |
1.8 |
1.5 |
0.9 |
1.2 |
|
0.6 |
1.5 |
1.2 |
0.7 |
1.3 |
|
4 |
1.5 |
1.6 |
1 |
1.2 |
|
| Controls |
(n = 9) |
71 |
59 |
27 |
13 |
43 |
(99) |
34 |
58 |
28 |
14 |
49 |
(109) |
120 |
61 |
30 |
12 |
41 |
(17) |
| SE | 2 | 3 | 1 | 1 | 3 | 2 | 1 | 1 | 0.4 | 3 | 7 | 5 | 5 | 2 | 3 | ||||
Clinical history of diabetes: 1, < 5 years; 2, 6–10 years; 3, 11–15 years; 4, > 15 years. β:Insulin, σ:Glucagon, δ:SRIF cells, (n): numbers of islets examined, % in β-, σ- and δ-cells were calculated the hormone-positive cells by the total islet cell numbers. % IAPP/β-cells was clculated dividing IAPP-positive cells by β-cell numbers.